QS Investors’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
$2.95M Buy
65,000
+1,100
+2% +$48.7K 0.03% 306
2021
Q1
$2.66M Buy
63,900
+44,668
+232% +$2.04M 0.03% 326
2020
Q4
$821K Hold
19,232
0.01% 569
2020
Q3
$506K Sell
19,232
-65,201
-77% -$1.82M 0.01% 683
2020
Q2
$2.26M Sell
84,433
-373
-0.4% -$8.41K 0.03% 441
2020
Q1
$1.53M Sell
84,806
-4,900
-5% -$93K 0.02% 522
2019
Q4
$1.62M Sell
89,706
-1,196
-1% -$20.7K 0.02% 645
2019
Q3
$1.41M Hold
90,902
0.02% 678
2019
Q2
$1.56M Sell
90,902
-2,400
-3% -$38.7K 0.02% 668
2019
Q1
$1.5M Hold
93,302
0.02% 711
2018
Q4
$1.37M Hold
93,302
0.02% 682
2018
Q3
$1.7M Hold
93,302
0.02% 659
2018
Q2
$1.57M Hold
93,302
0.02% 666
2018
Q1
$1.83M Sell
93,302
-9,404
-9% -$182K 0.02% 609
2017
Q4
$2.08M Buy
102,706
+5,645
+6% +$104K 0.02% 596
2017
Q3
$1.69M Hold
97,061
0.01% 663
2017
Q2
$1.24M Sell
97,061
-2,685
-3% -$35.9K 0.01% 716
2017
Q1
$1.29M Hold
99,746
0.01% 722
2016
Q4
$985K Hold
99,746
0.01% 758
2016
Q3
$1.21M Sell
99,746
-827
-0.8% -$8.45K 0.01% 742
2016
Q2
$868K Hold
100,573
0.01% 796
2016
Q1
$952K Sell
100,573
-27,918
-22% -$263K 0.01% 785
2015
Q4
$2.23M Buy
128,491
+23,512
+22% +$375K 0.02% 634
2015
Q3
$1.41M Sell
104,979
-51,900
-33% -$1.04M 0.01% 710
2015
Q2
$3.54M Buy
156,879
+51,900
+49% +$912K 0.04% 470
2015
Q1
$1.5M Hold
104,979
0.02% 655
2014
Q4
$1.01M Buy
+104,979
New +$933K 0.01% 728

Other funds holding HALO

QS Investors's HALO Position: Q2 2021 in Review

QS Investors increased its Halozyme (HALO) stake by 1.7% in Q2 2021, buying an estimated $48.7K and bringing the position to 65,000 shares worth $2.95M. The position accounts for 0.03% of the portfolio, ranked #306.

QS Investors first reported a position in HALO in Q4 2014 and has held it in 27 quarters since. The position peaked at $3.54M in Q2 2015. 313 funds tracked by Wall St. Rank hold HALO as of Q2 2021.

  • QS Investors held 65,000 shares of Halozyme worth $2.95M as of Q2 2021.
  • QS Investors bought 1,100 Halozyme shares in Q2 2021, an estimated $48.7K.
  • Halozyme made up 0.03% of QS Investors's portfolio in Q2 2021, its #306 holding.
  • QS Investors first reported a position in Halozyme in Q4 2014 and has held it in 27 quarters since.
  • QS Investors's Halozyme position peaked at $3.54M in Q2 2015.
  • 313 funds tracked by Wall St. Rank held Halozyme as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.